Background The roles of anticoagulation alone or with an antiplatelet agent after
transcatheter aortic-valve implantation (TAVI) have not been well studied. Methods We …

Background It is unknown whether patients undergoing primary percutaneous coronary
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …

Background The effect of single as compared with dual antiplatelet treatment on bleeding
and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients …

Background: Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells.
There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among …

Background Patients with obstructive left main coronary artery disease are usually treated
with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug …

Background Current guidelines recommend potent platelet inhibition with prasugrel or
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …

Background Drug-coated balloons (DCB) are a novel therapeutic strategy for small native
coronary artery disease. However, their safety and efficacy is poorly defined in comparison …

5. Leczenie.............................................................. 1225 5.1. Farmakoterapia
niedokrwienia...................... 1225 5.1. 1. Ogólne leczenie objawowe................. 1225 5.1. 2 …

Methods We limited our literature review to trials in patients with AF and VTE because the
work of the Bleeding Academic Research Consortium has already addressed this issue in …

Background Limited data are available on the long-term effects of contemporary drug-eluting
stents versus contemporary bare-metal stents on rates of death, myocardial infarction, repeat …